199 related articles for article (PubMed ID: 14730477)
1. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
Büller HR
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
[No Abstract] [Full Text] [Related]
2. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
3. Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
Schulman S
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():33-6. PubMed ID: 14730476
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
5. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
Greaves M;
Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
[No Abstract] [Full Text] [Related]
6. [Where to look for progress in antithrombotic treatments?].
Samama MM
Rev Prat; 1999 Oct; 49(15):1664-8. PubMed ID: 10581998
[TBL] [Abstract][Full Text] [Related]
7. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
Ammollo CT; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
[No Abstract] [Full Text] [Related]
8. Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.
Dalmora SL; Junior LB; Vaccari SF; Fronza M; Renato de Oliveira P; Rolim CM
Farmaco; 2005 Mar; 60(3):225-9. PubMed ID: 15784241
[TBL] [Abstract][Full Text] [Related]
9. Factor Xa inhibitors: next-generation antithrombotic agents.
Pinto DJ; Smallheer JM; Cheney DL; Knabb RM; Wexler RR
J Med Chem; 2010 Sep; 53(17):6243-74. PubMed ID: 20503967
[No Abstract] [Full Text] [Related]
10. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in anticoagulation.
Ansell JE
Manag Care; 2004 Sep; 13(9 Suppl):8-12. PubMed ID: 15493218
[No Abstract] [Full Text] [Related]
12. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
Jiang X; Crain EJ; Luettgen JM; Schumacher WA; Wong PC
Thromb Haemost; 2009 Apr; 101(4):780-2. PubMed ID: 19350128
[No Abstract] [Full Text] [Related]
13. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.
Masters JJ; Franciskovich JB; Tinsley JM; Campbell C; Campbell JB; Craft TJ; Froelich LL; Gifford-Moore DS; Hay LA; Herron DK; Klimkowski VJ; Kurz KD; Metz JT; Ratz AM; Shuman RT; Smith GF; Smith T; Towner RD; Wiley MR; Wilson A; Yee YK
J Med Chem; 2000 Jun; 43(11):2087-92. PubMed ID: 10841787
[No Abstract] [Full Text] [Related]
14. Antithrombin and anti-Xa agents in the control of thrombogenesis.
Fareed J; Shaikh T; Hoppensteadt DA
Pharmazie; 2001 Oct; 56 Suppl 1():S12-21. PubMed ID: 11686086
[TBL] [Abstract][Full Text] [Related]
15. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
16. New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Ansell J
Curr Hematol Rep; 2004 Sep; 3(5):357-62. PubMed ID: 15341703
[TBL] [Abstract][Full Text] [Related]
17. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
19. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
20. Approaches in anticoagulation: rationales for target positioning.
Wieland HA; Laux V; Kozian D; Lorenz M
Curr Opin Investig Drugs; 2003 Mar; 4(3):264-71. PubMed ID: 12735227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
